Literature DB >> 3390826

Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma.

C McKeon1, C J Thiele, R A Ross, M Kwan, T J Triche, J S Miser, M A Israel.   

Abstract

Genetic characterization of human tumors promises new insights of biological importance and clinical relevance. We have found that two solid tumors, peripheral neuroepithelioma and Ewing's sarcoma of bone, which share a common cytogenetic rearrangement, are characterized by an indistinguishable and highly reproducible pattern of protooncogene expression. c-myc, N-myc, c-myb, and c-mil/raf-1 are all expressed at similar levels in these tumors. c-fes and c-sis expression was not detected in any specimens of either tumor. In contrast, the protooncogene c-ets-1, located near the breakpoint of the chromosomal translocation in these tumors, is variable in its expression. We also detected high levels of choline acetyltransferase in these tumors, which suggests a common neural origin. Since it is likely that the clinical behavior and therapeutic responsiveness of tumors relate closely to their biological and genetic features, the pattern of protooncogene expression of individual tumors may provide a novel basis for their characterization.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390826

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  A novel POU homeodomain gene specifically expressed in cells of the developing mammalian nervous system.

Authors:  R G Collum; P E Fisher; M Datta; S Mellis; C Thiele; K Huebner; C M Croce; M A Israel; T Theil; T Moroy
Journal:  Nucleic Acids Res       Date:  1992-09-25       Impact factor: 16.971

2.  Regulation of the release of tumour necrosis factor (TNF)alpha and soluble TNF receptor by gamma irradiation and interferon gamma in Ewing's sarcoma/peripheral primitive neuroectodermal tumour cells.

Authors:  F van Valen; V Kentrup-Lardong; B Truckenbrod; C Rübe; W Winkelmann; W W Jürgens
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Extraosseous retroperitoneal Ewing's sarcoma.

Authors:  F García-Moreno Nisa; P López Quindos; D García Teruel; R Beni Pérez
Journal:  Clin Transl Oncol       Date:  2007-06       Impact factor: 3.405

4.  EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.

Authors:  K Tanaka; T Iwakuma; K Harimaya; H Sato; Y Iwamoto
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

5.  Expression of the cholecystokinin gene in pediatric tumors.

Authors:  J M Friedman; M Vitale; J Maimon; M A Israel; M E Horowitz; B S Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 6.  Biology of pediatric peripheral neuroectodermal tumors.

Authors:  C J Thiele
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

Review 7.  Biology of tumors of the peripheral nervous system.

Authors:  G M Brodeur; J F Moley
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

8.  DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.

Authors:  R A Bailly; R Bosselut; J Zucman; F Cormier; O Delattre; M Roussel; G Thomas; J Ghysdael
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

9.  Peripheral primitive neuroectodermal tumour and extra-osseous Ewing's sarcoma; a histological, immunohistochemical and DNA flow cytometric study.

Authors:  M Brinkhuis; L C Wijnaendts; J C van der Linden; A J van Unnik; P A Voûte; J P Baak; C J Meijer
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Expression of functional Y1 receptors for neuropeptide Y in human Ewing's sarcoma cell lines.

Authors:  F van Valen; W Winkelmann; H Jürgens
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.